AGIO - アギオス・ファ―マシュ―ティカルズ (Agios Pharmaceuticals Inc.) アギオス・ファ―マシュ―ティカルズ

 AGIOのチャート


 AGIOの企業情報

symbol AGIO
会社名 Agios Pharmaceuticals Inc (アギオス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジオス・ファーマスーティカルズ(Agios Pharmaceuticals Inc.)はバイオ医薬品会社。同社は根本的に癌と先天性代謝異常(IEM)の治療法を変えるために代謝に対する深い理解と代謝酵素を阻害・活性化できる薬剤を開発する能力を結合して応用しようとする。同社はすでに癌と先天性代謝異常に対して新薬開発の目標を明確・有効にした。同社の2つの進んだ癌プログラムは「IDH1」と「IDH2」と呼ばれるイソクエン酸脱水素酵素1と2の変異を標的とする。同社の薬剤候補は他の細胞に見られるIDH1とIDH2の正常形態に対し、癌に見られるIDH1とIDH2の変異形態を特定する。   アギオス・ファ―マシュ―ティカルズは、がん代謝と先天性代謝異常の分野に特化した米国のバイオ医薬品企業。主製品候補は、変異型イソクエン酸脱水素酵素2「AG-221」及びイソクエン酸デヒドロゲナ―ゼ1「AG-120」。急性骨髄性白血病などの突然変異IDH2を保有する癌または、突然変異IDH1を保有する癌患者用の強力な阻害剤。   Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
本社所在地 88 Sidney Street Cambridge MA 02139 USA
代表者氏名 David P. Schenkein David P. Schenkein
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-649-8600
設立年月日 39295
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 382人
url www.agios.com
nasdaq_url https://www.nasdaq.com/symbol/agio
adr_tso
EBITDA EBITDA(百万ドル) -329.37600
終値(lastsale) 68.07
時価総額(marketcap) 3947554648.32
時価総額 時価総額(百万ドル) 3819.391
売上高 売上高(百万ドル) 70.33300
企業価値(EV) 企業価値(EV)(百万ドル) 3102.486
当期純利益 当期純利益(百万ドル) -324.99200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agios Pharmaceuticals Inc revenues increased from $21.9M to $49.2M. Net loss increased 7% to $159.6M. Revenues reflect Collaboration revenue - related party increase of 54% to $33.7M. Higher net loss reflects Research and development increase of 15% to $146.6M (expense) General and administrative increase of 66% to $38.5M (expense).

 AGIOのテクニカル分析


 AGIOのニュース

   ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. “We
   Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results  2021/02/26 21:49:29 Transcript Daily
Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.10), MarketWatch Earnings reports. The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had […]
   Canaccord Genuity Stick to Their Buy Rating for Agios Pharma By Investing.com  2021/02/26 11:37:51 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Agios Pharma
   Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com  2021/02/19 10:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. “We
   Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results  2021/02/26 21:49:29 Transcript Daily
Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.10), MarketWatch Earnings reports. The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had […]
   Canaccord Genuity Stick to Their Buy Rating for Agios Pharma By Investing.com  2021/02/26 11:37:51 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Agios Pharma
   Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com  2021/02/19 10:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. “We
   Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results  2021/02/26 21:49:29 Transcript Daily
Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.10), MarketWatch Earnings reports. The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had […]
   Canaccord Genuity Stick to Their Buy Rating for Agios Pharma By Investing.com  2021/02/26 11:37:51 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Agios Pharma
   Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com  2021/02/19 10:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アギオス・ファ―マシュ―ティカルズ AGIO Agios Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)